Breakell T, Waibel H, Schliep S, Ferstl B, Erdmann M, Berking C, Heppt M (2022)
Publication Type: Journal article
Publication year: 2022
Book Volume: 29
Pages Range: 2909-2919
Journal Issue: 5
DOI: 10.3390/curroncol29050237
Intravascular large B-cell lymphoma (IVLBCL) is an aggressive Non-Hodgkin lymphoma (NHL) characterised by the presence of neoplastic lymphoid cells within small-and medium-sized blood vessels. According to the clinical presentation, the current WHO classification distinguishes the ‘classic’ (formerly ‘Western’) from a hemophagocytic syndrome-associated (formerly ‘Asian’) variant. A third ‘cutaneous’ variant has been proposed, characterised by a good prognosis and unique clinical features. While laboratory findings can hint at diagnosis, symptoms are rather nonspecific, and deep skin biopsy supported by further measures such as bone marrow aspiration and positron emission tomography-computed tomography scanning is needed to make a definite diagnosis. Treatment is comprised of anthracycline-based chemotherapy supplemented with rituximab and central nervous system prophylaxis. While there are various prognostic models for NHL, only one is specific to IVLBCL, which does not sufficiently represent some patient groups, especially regarding the lack of differentiation within the patient collective with skin involvement. This underlines the necessity for the establishment of further prognostic models in particular for IVLBCL patients with cutaneous manifestations.
APA:
Breakell, T., Waibel, H., Schliep, S., Ferstl, B., Erdmann, M., Berking, C., & Heppt, M. (2022). Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement. Current Oncology, 29(5), 2909-2919. https://doi.org/10.3390/curroncol29050237
MLA:
Breakell, Thomas, et al. "Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement." Current Oncology 29.5 (2022): 2909-2919.
BibTeX: Download